SCHEMBL199122

SCHEMBL199122

OC[C@H]1O[C@](O)(OP(O)(O)=S)C[C@@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2424173 0.89 — —
SCHEMBL6045772 0.83 — —
SCHEMBL6045394 0.79 NPSR1 (0.33) —
SCHEMBL27743482 0.79 — —
SCHEMBL1039509 0.78 BTN3A1 (0.32) —
SCHEMBL10380113 0.76 — —
SCHEMBL320910 0.76 P2RY2 (0.31) —
SCHEMBL27915482 0.75 PYGB (0.33) —
SCHEMBL27933879 0.75 PYGB (0.33) —
SCHEMBL25388821 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617426-A1 INHIBITOR OF HMGB PROTEIN-MEDIATED IMMUNE RESPONSE ACTIVATION, AND SCREENING METHOD Japan Science and Technology Agency (JP) 2013-07-24 — — EP claimed
US-20130183348-A1 Inhibitor of HMGB Protein-Mediated Immune Response Activation, and Screening Method JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2013-07-18 — — US claimed
CN-103096899-A Inhibitor of hmgb protein-mediated immune response activation, and screening method JAPAN SCIENCE & TECH AGENCY 2013-05-08 — — CN claimed
WO-2008116165-A9 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION NEXT SAFETY INC (US) 2009-06-11 — — WO claimed
WO-2008116165-A2 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION NEXT SAFETY, INC. (US) 2008-09-25 — — WO claimed
US-20080066741-A1 METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION HUNTER, CHARLES ERIC 2008-03-20 — — US claimed
US-20060183886-A1 Ligands to enhance cellular uptake of biomolecules CELL WORKS THERAPEUTICS, INC., A DELAWARE CORPORATION 2006-08-17 — — US claimed
EP-1409548-A4 LIGANDS TO ENHANCE CELLULAR UPTAKE OF BIOMOLECULES CELL WORKS THERAPEUTICS INC (US) 2005-08-31 — — EP claimed
EP-1409548-A2 LIGANDS TO ENHANCE CELLULAR UPTAKE OF BIOMOLECULES Cell Works Inc. (US) 2004-04-21 — — EP claimed
WO-2003067209-A2 LIGANDS TO ENHANCE CELLULAR UPTAKE OF BIOMOLECULES CELL WORKS INC. (US) 2003-08-14 — — WO claimed
US-20030119724-A1 Ligands to enhance cellular uptake of biomolecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-06-26 — — US claimed
US-20240123168-A1 PRODUCT DELIVERY DEVICES AND METHODS MUSTAPHA JIHAD A (US) 2024-04-18 — — US disclosed
WO-2024073386-A1 IMPLANTABLE MEDICAL DEVICE FOR THE DELIVERY OF A NUCLEIC ACID CELANESE EVA PERFORMANCE POLYMERS LLC (US) 2024-04-04 — — WO disclosed
CN-117616122-A Antisense oligonucleotides (ASOs) for efficient and accurate RNA editing using endogenous Adenosine Deaminase (ADAR) acting on RNA 艾伯哈特卡尔斯图宾根大学 2024-02-27 — — CN disclosed
CN-117479837-A RNAi nanoparticles and methods of use thereof in agriculture 耶路撒冷希伯来大学伊萨姆研发有限公司 2024-01-30 — — CN disclosed
US-20050221293-A1 DNA virus microRNA and methods for inhibiting same ROCKEFELLER UNIVERSITY, THE 2005-10-06 — — US disclosed
US-20050222067-A1 DNA virus microRNA and methods for inhibiting same THE ROCKEFELLER UNIVERSITY 2005-10-06 — — US disclosed
US-20050221490-A1 DNA virus microRNA and methods for inhibiting same ROCKEFELLER UNIVERSITY, THE 2005-10-06 — — US disclosed
WO-2005079397-A2 ANTI-MICRORNA OLIGONUCLEOTIDE MOLECULES ROCKEFELLER UNIVERSITY (US) 2005-09-01 — — WO disclosed
US-20050182005-A1 Anti-microRNA oligonucleotide molecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-08-18 — — US disclosed
Send feedback